SCHEMBL20109175

SCHEMBL20109175

C=C(C(Cc1ccccc1-c1ccccc1)C(=O)OCC)P1(=O)OCCO1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 5/20 0.39
HPGD P15428 4/20 0.39
MAPT P10636 3/20 0.39
HSD17B10 Q99714 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP2D6 P10635 3/20 0.38
SLC6A2 P23975 3/20 0.38
SLC6A4 P31645 3/20 0.38
SLC6A3 Q01959 2/20 0.38
CHRM3 P20309 1/20 0.38
KCNH2 Q12809 1/20 0.38
MMP8 P22894 1/20 0.37
LMNA P02545 1/20 0.37
MME P08473 1/20 0.36
ACE P12821 1/20 0.36
CPA1 P15085 1/20 0.36
ACE2 Q9BYF1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20113526 0.84 MMP8 (0.53) KMT2AALDH1A1HPGDMAPTHSD17B10
SCHEMBL20109199 0.83 KMT2A (0.48) KMT2AALDH1A1HPGDMAPTCYP1A2
SCHEMBL20109146 0.81 KMT2A (0.46) KMT2AALDH1A1HPGDMAPTHSD17B10
SCHEMBL21866414 0.78 KMT2A (0.45) KMT2AALDH1A1HPGDMAPTCYP1A2
SCHEMBL20109258 0.77 KMT2A (0.44) KMT2AALDH1A1HPGDMAPTCYP1A2
SCHEMBL20109172 0.77 MMP8 (0.41) KMT2AALDH1A1HPGDMAPTHSD17B10
SCHEMBL20113453 0.76 EPHX2 (0.41) KMT2AALDH1A1HPGDMAPTHSD17B10
SCHEMBL20113625 0.75 PPARG (0.41) KMT2AALDH1A1HPGDMAPTHSD17B10
SCHEMBL20113398 0.74 MMP8 (0.51) KMT2AALDH1A1HPGDMAPTHSD17B10
SCHEMBL20113627 0.72 PPARG (0.44) KMT2AALDH1A1MAPTMMP8PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10633403-B2 N-heterocyclic phosphines THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA (US) 2020-04-28 US disclosed
US-20180118770-A1 N-Heterocyclic Phosphines THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS 2018-05-03 US disclosed
US-20180118770-A1 N-Heterocyclic Phosphines THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118770-A1 N-Heterocyclic Phosphines NANP, PPIP5K2, PHPT1 KMT2A 2508/4885ALDH1A1 4621/4885HPGD 504/4885
US-10633403-B2 N-heterocyclic phosphines NANP, PPIP5K2, PHPT1 KMT2A 2508/4885ALDH1A1 4621/4885HPGD 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.